MAPKAPK3 and cancer: As the cancer cell line models used herein are all known to be defective in their P14ARF/TP53 and/or p16/pRB checkpoints, the opposing responses of normal fibroblasts and cancer cells to MK3-depletion suggest an involvement of CDKN2A/INK4A.